Literature DB >> 34512153

The role of RNA m5C modification in cancer metastasis.

Qiaofeng Zhang1,2,3, Furong Liu1,2,3, Wei Chen1,2,3, Hongrui Miao1,2,3, Huifang Liang1,2,3, Zhibin Liao1,2,3, Zhanguo Zhang1,2,3, Bixiang Zhang1,2,3.   

Abstract

Epigenetic modification plays a crucial regulatory role in the biological processes of eukaryotic cells. The recent characterization of DNA and RNA methylation is still ongoing. Tumor metastasis has long been an unconquerable feature in the fight against cancer. As an inevitable component of the epigenetic regulatory network, 5-methylcytosine is associated with multifarious cellular processes and systemic diseases, including cell migration and cancer metastasis. Recently, gratifying progress has been achieved in determining the molecular interactions between m5C writers (DNMTs and NSUNs), demethylases (TETs), readers (YTHDF2, ALYREF and YBX1) and RNAs. However, the underlying mechanism of RNA m5C methylation in cell mobility and metastasis remains unclear. The functions of m5C writers and readers are believed to regulate gene expression at the post-transcription level and are involved in cellular metabolism and movement. In this review, we emphatically summarize the recent updates on m5C components and related regulatory networks. The content will be focused on writers and readers of the RNA m5C modification and potential mechanisms in diseases. We will discuss relevant upstream and downstream interacting molecules and their associations with cell migration and metastasis. © The author(s).

Entities:  

Keywords:  5-methylcytosine; Metastasis; cell migration; regulatory network; ribosome acid

Mesh:

Substances:

Year:  2021        PMID: 34512153      PMCID: PMC8416729          DOI: 10.7150/ijbs.61439

Source DB:  PubMed          Journal:  Int J Biol Sci        ISSN: 1449-2288            Impact factor:   6.580


Background

In eukaryotes, a wide range of nucleotide modifications, including acetylation, methylation and glycosylation, are essential for cellular biological processes and carcinogenesis. Among the hundreds of chemical modifications, 5-methylcytosine (m5C) is a highly focused epigenetic modification that has been identified in DNA and various RNA families. 5-Methylcytosine in DNA (5mC) is well established as a regulator of gene expression and genome stability 1, 2. Otherwise, the m5C modification is also present in transcript. The biological roles of this modification in RNA, including RNA export, translation, RNA fragmentation and ribosome composition, were not fully comprehended until recently 3-5. Using metabolic or radioactive labeling detection, canonical bisulfite sequencing, methylated RNA immunoprecipitation sequencing (MeRIP-seq) and liquid chromatograph mass spectrometer (LC-MS), an increasing number of mapping approaches for m5C have been improved and employed to further elucidate the functions of the m5C modification 6-9. For example, a newly developed solid-phase method for single RNA molecule sequencing may be used as a solution to the insufficient sensitivity of second-generation sequencing to detect RNA modification 10. As researchers have increasingly recognized the RNA m5C modification, extensive target sites were discovered in multiple RNA classes and diverse organisms 11-17, revealing the crucial effect of the RNA m5C modification on eukaryotes. An integrated m5C regulatory network has been revealed, and their writers (methyltransferase), demethylases and readers (proteins that specifically bind to methylation sites) have been identified. Earlier studies have detected DNA methylation induced by the human homologous DNA methyltransferase (DNMT) family, including DNMT1, DNMT2 and DNMT3A/3B. Exclusively, a multiomics study revealed that human DNMT2 not only methylates DNA but also a small RNA (aspartic acid transfer RNA) 18. In recent years, a notable methyltransferase family, NOP2/Sun RNA methyltransferases (NSUNs), has been shown to methylate multiple sites in transfer RNA 13, 17, 19. Additionally, some NSUN family members have target sites on mRNA, rRNA, mitochondrial RNA, noncoding RNA and even viral RNA 7, 20-22. For m5C demethylation, ten-eleven translocation (TET) genes were initially implicated as tumor suppressors 23, but subsequently determined to mediate oxidation to 5-hydroxymethyl, 5-formyl, and 5-carboxylcytosine (hm5C, f5C and ca5C), followed by the excision of f5C or ca5C which is probably induced by thymine DNA glycosidase (TDG) in DNA 24. Studies at m5C readers and subsequent physiological functions further indicate the complicacy of cascading regulation at the molecular level. The RNA m5C modification is involved in a large number of human cancers, including leukemia, lung cancer, gastric cancer, squamous cell carcinomas, hepatocellular carcinoma and gynecologic cancers 25-29. The conceivable demethylase TET-mediated oxidation and absence of DNA 5mC are associated with cancer progression 30-34. In summary, the m5C modification and its elimination are closely associated with molecular and cytological processes in diseases and various cancer types, and thus research on the mechanism and clinical application are hotspots. In this review, we focus on the pivotal mechanisms of RNA m5C modifications involved in metastasis, cell migration and invasion, discussing their functions in cellular biological processes and tumor development. Classified by enzyme family, we review the recent progress in studies of m5C writers, demethylases and readers to summarize the current knowledge on methylation associated molecular regulation and pathway activation, as well as the reversion of demethylation. We then discuss the clinical advances in the evaluation and prognosis of human cancers.

Reversible methylation of nucleic acids

N6-methyladenosine

In earlier studies, the DNA N6-methyladenosine (m6A) modification was established as a pivotal modification in prokaryotes but was not detectable in eukaryotes. Importantly, m6A modifications have now been identified as closely related to many biological processes and diseases, such as RNA metabolism related gene expression regulation, DNA damage repair, cell development and differentiation, cell cycle, immune response and even cancer progression 5, 35-38. For instance, research on DNA m6A in the human genome indicated that specific enzymes induce methylation and demethylation-mediated gene transcription by targeting the AGG motif 39. The well-known m6A methyltransferase and demethylase, methyltransferase-like 3 (METTL3) and fat mass and obesity-associated protein (FTO), respectively, are involved in the DNA damage response to ultraviolet irradiation 40. In contrast, as the most abundant RNA modification in eukaryotes, m6A plays a crucial role in epigenetic regulation at the transcriptional level. To date, various RNA classes have been verified to be regulated by m6A modification, including precursor mRNAs, long noncoding RNAs, ribosomal RNA and microRNAs 41-43. The diversity of modification sites implies multiple biological functions that reveal an intricate regulatory network of m6A. Similarly, METTL3-induced m6A promotes the mRNA translation of several oncogenes in human acute myeloid leukemia cells, and then mediates cell proliferation, apoptosis and leukemia progression 44. FTO functions as a regulator of poly(A) site and 3' UTR processing and exon splicing in nuclear mRNAs 45.

5-methylcytosine

Studies of the DNA 5mC modification have focused on the transformation of the second structure at first. As physiological and pathological effects are being revealed, DNA 5mC-associated methyltransferases are being identified, including DNMT1, DNMT2, DNMT3A and DNMT3B 46. For instance, the structural and biochemical data of the DNMT1-DNA complex indicate the methylation maintenance function in methylase-induced DNA methylation 47. Otherwise, DNMT1 translocates to the mitochondrial matrix and binds to mitochondrial DNA, which is associated with asymmetric regulation of the translation of heavy chains and light chains in mtDNA 48. In the nucleus, a specific complex composed of DNMT3A or 3B and nucleosomes stabilizes free DNMT3A/3B enzymes, protects them from elimination and promotes further DNA methylation 49. Interestingly, DNMT2 was confirmed to bind DNA in human eukaryotic cells 50. However, according to whole-genome bisulfite sequencing, DNMT2-involved genome modification lacked detectable DNA methylation patterns in a large number of eukaryotes 51. In addition, a human homologue of this methylase, tRNA aspartic acid methyltransferase 1 (TRDMT1), has been reported to share a sequence and function similar to DNMT2 in mediating tRNA m5C. We view these two molecules as one RNA m5C methylase, which is accepted by mainstream academics.18, 52. Meanwhile, the NSUN family has been revealed to mediate m5C modification in different RNA classes, including tRNA, mRNA, rRNA, vault RNA and enhancer RNA 14, 17, 53-55. The main targets of NSUNs are the 3' untranslated region of mRNA and various cytosines of tRNA. As the most well-known NSUN family menber, NSUN2 (yeast homologue TRM4) participates in cell cycle progression and tumor growth, probably by targeting at known C34, 48, 49, 50 of tRNA in a range of tumors, such as human squamous cell carcinoma and breast cancer 56, 57. While other NSUNs have a variety of functions at post-transcriptional level 11, 14, 22, 29, 58-60.

N1-methyladenosine

For the N1-methyladenosine (m1A) modification, related functional research has become more common in the last five years. The biological effect of the reversible m1A modification is to meditate RNA stability and RNA processing, and this modification has been verified to have a transcriptome-wide distribution in mammalian cells and tissues 61, 62. According to recent studies, m1A is distributed in mRNAs and enriched at translation start sites (5' UTRs), which may promote translation 63, 64. In addition to the many target sites in mRNAs, m1A also occurs in several regions of tRNAs and mitochondrial genes and regulates corresponding biological processes 65. Nevertheless, as an essential component of epigenetic modifications, the biological functions of m1A remain ambiguous. The m1A level in mitochondrial tRNAs is significantly altered in various human cancers, and is associated with the clinical prognosis 66. For example, by catalyzing the demethylation of m1A in tRNA, alkB homolog 1 (ALKBH1) facilitates cancer progression and migration in vivo, resulting in demethylation-induced tRNA fragmentation 67. In summary, the clinical relevance of the RNA m1A modification remains unclear and requires further identification.

m5C writers, demethylases and readers

Methyltransferases mediating the RNA m5C modification

The formation of m5C indicates the installation of a methyl group on the fifth carbon of cytosine in CpG islands, which is regulated by m5C methyltransferases and demethylases. The so-called m5C “writer” typically possesses highly conserved functional regions that are present in other members of the enzyme family. Numerous m5C writers participate in the methylation of extensive RNAs and epigenetic regulation (Figure 1). DNMT2 proteins contain a DNMT family conserved region in the target recognition domain, which shares the DNA-MTase catalytic triad to methylate tRNA substrates 68. An in vitro RNA electrophoretic mobility shift assay confirmed that DNMT2 preferentially binds specific mRNAs other than DNA 69. A similar pattern of double-substrate targeting has been observed for other epigenetic modifications, such as m6A, hm5C and m1A 70-75. To date, 7 human NSUN variants have been identified that recognize RNAs through aspartate side chains in motif VI and target at specific cytosines 76. Despite sharing conserved functional sites with other family members, NSUN2 significantly upregulates the abundance of m5C in mRNAs rather than in total RNAs 7. In addition to mRNA methylation, NSUN2-induced m5C installation in tRNAs and vault RNAs has also been verified 15, 21, 77. In eukaryotic cells, NSUN1 (yeast homologue NOP2), NSUN4 and NSUN5 (yeast homologue RCM1) target 25S and 28S rRNAs 11, 14, 22. NSUN3 and NSUN6 individually methylate cytosine 34 of mitochondrial tRNA and cytosine 72 of cytoplasmic tRNA, which improves their stability 60, 78. These targeting sites at positions 2278 and 2870 in 25S rRNA and position 3782 in 28S rRNA are in highly conserved ribosome regions, suggesting the functional importance of rRNA m5C modification 79. Unlike mRNA methylation, m5C enrichment in tRNAs is a structure-specific modification. Targeting sites are mostly located in the T stem loop at positions 48-50 and anticodon loop positions 34 and 38. Sites have also been reported at position 72 of the acceptor arm and at the D stem loop. NSUN7 interacts with promoter-derived enhancer RNAs to indirectly regulate gene expression indirectly 55. The function of NSUN proteins requires an RNA-recognition motif and Rossman-fold catalytic core, which is slightly different from the catalytic site of DNMT2 80. Furthermore, a novel cofactor mechanism is essential for the NSUN-mediated m5C modification, such as the S-adenosylmethionine induced methyl transfer process 81.
Figure 1

RNA m5C modifications with functions of m5C writers and readers. M5C methylation in tRNA, rRNA, mRNA and ncRNA is involved in RNA processing and metabolism. Binding proteins (YTHDF2, ALYREF, YBX1) for m5C modification take part in m5C modification in methylase-dependent or independent way. A multicomponent regulatory network is constructed to affect epigenetic regulation.

m5C reversion and the TET family

The oxidation of m5C to hm5C, f5C and ca5C is an essential epigenetic modification in eukaryotes. TET protein-mediated demethylation of DNA 5mC was verified in early studies 82, 83. Notably, the appellation of “5-methylcytosine eraser” for TETs is not widely accepted because the essence of TET induced demethylation is to replace the modification by facilitating subsequent oxidations. The oxidation cascade relies on the conserved catalytic core at the carboxyl terminus, which depends on a cofactor. A recent study revealed that reduced iron and α-ketoglutarate are recruited by the double-stranded β‑helix domain in the TET catalytic region for oxidation 84. Interestingly, human TETs prefer hydroxyl and formyl depositions, suggesting a substrate-specific feature 85. Three influential mechanisms for demethylation of the 5mC oxidized base have been proposed: direct removal of the oxidized methyl group, a passive replication-dependent dilution process, and DNA repair-associated excision of modified nucleotides. Active removal is mediated by TDG coupled with base excision repair, which is specific to the formation of f5C and ca5C 86, 87. In addition, passive degradation of oxidized substrates occurs frequently during persistent DNA replication. This particular process was reported to be related to 5mC demethylation 88. Finally, base excision repair-induced removal of 5mC residues has been widely accepted, although the detailed mechanism of accurate residue elimination has not been elucidated. In addition, non-canonical DNA mismatch repair-induced removal of alkylated and oxidized nucleotides is one of the probable pathways mediating active DNA demethylation 89. Recently, TET protein-induced RNA hm5C modification has been reported in specific eukaryotic cells, including mouse embryonic stem cells, bone marrow mononuclear cells, Drosophila and mouse brain cells 70, 75, 90, 91. For example, the distribution and enrichment of RNA hm5C in mouse brain tissues was verified by a dot blot analysis, and this modification is associated with Parkinson's disease. In human tissues and cells, a low level of RNA hm5C was detected using improved LC-MS/MS methods 92, 93. Researches have not clearly determined whether hm5C modifications in RNA and DNA use the same mechanism and regulatory patterns. A recent study suggested that isocitrate dehydrogenases block TET-induced oxidative activity in both DNA and mRNA based on the results of an LC-MS/MS analysis 94. Hence, further study at the molecular level is needed to assess the functional pattern of RNA hm5C. However, few mature sequencing methods at single-base resolution are available for oxidized m5C mapping, and thus the study of the mechanism of RNA m5C demethylation becomes quite challenging. Immunoprecipitation is an RNA-friendly sequencing method to further reveal the elusive biological functions of m5C oxidation and demethylation 90. Moreover, a novel bisulfite-free and high-resolution method uses peroxotungstate to conduct the hm5C-to-T transition, following cDNA synthesis and base-resolution sequencing 9, which is helpful to comprehensively identify the hm5C distribution and function.

Proteins binding to RNA m5C sites

After the m5C modification of RNA, several proteins specifically bind to modified sites, leading to the subsequent regulation of biological processes (Figure 1). We named these particular proteins “readers” due to their capability of recognizing m5C-containing oligonucleotides. According to a recent study, the m6A binding protein, YTH domain-containing family 2 (YTHDF2), shares a conserved residue at the hydrophobic pocket for binding m5C-modified RNA 95. Specifically, Aly/REF export factor (ALYREF) displayed a significantly enhanced binding ability to m5C-modified mRNAs across the cytoplasm and nucleus, which was confirmed by ALYREF protein sequencing 7. Found in zebrafish early embryos, Y-box binding protein 1 (YBX1), a well-known multifunctional DNA and RNA binding protein , can recognize and bind m5C modified mRNAs by residue Trp45 in the cold shock domain of YBX1 96, 97. Overall, the m5C regulatory network mainly consists of functional readers and downstream effector, which needs further investigation of novel specific binding proteins.

Biological function of m5C in eukaryote and disease

The m5C modification is widely distributed in RNA involved in various biological processes. As a fundamental function of the RNA m5C modification, the regulation of RNA function and metabolism is crucial to the development of biological processes (Figure 1). With improved detection approaches for RNA methylation assays, more types of RNA have been identified as m5C targets. The RNA m5C modification induced by NSUN1 (yeast homologue Nop2) and NSUN5 (yeast homologue Rcm1) regulate ribosome synthesis and processing 11, 14. NSUN4 even participates in mitochondrial ribosome biogenesis 29, 58. The processing of mature RNA is also associated with m5C methylation in mRNAs and noncoding RNAs (ncRNAs). For example, DNMT2 is responsible for RNA processing by relocating and interacting with mRNA as a component of the processing complex 98. The processing of noncoding vault RNA in human cells is induced by the m5C modification at C69, which maintains the cell cycle in progenitor cells 21. The m5C modification promotes RNA stabilization, transportation and translation, but not translation termination induced by NSUN6 mediated mRNA methylation to allow RNAs to perform their regular functions 99. For instance, NSUN2 targets the 3' untranslated region and stabilizes the mRNA of heparin binding growth factor, which regulates cancer progression 54. The reader YBX1 recognizes and binds m5C-modified mRNAs at Trp45 to enhance mRNA stability and early embryogenesis in zebrafish 96. For nucleus-to-cytoplasm transportation, the reader ALYREF interacts with NSUN2-methylated mRNA to mediate shuttling and subsequent translation in the cytoplasm 100. In addition, protein translation and polypeptide synthesis involving tRNAs are regulated by DNMT2-induced m5C of the anticodon stem-loop 12, 77, 101. The RNA m5C modification is involved in epigenetic regulation by affecting RNA metabolism. RNA fragmentation is a common metabolic pattern of tRNA that is related to epigenetic regulation and cancer progression 102. DNMT2 and NSUN2 were reported to be associated with the biogenesis of tRNA-derived noncoding fragments by altering tRNA fragmentation 103, 104. In addition, NSUN3 targets mitochondrial tRNA, which may be responsible for energy metabolism and protein synthesis 22, 59, 60. Since RNA function and epigenetic regulation are strongly associated with the occurrence and development of diseases, the role of the RNA m5C modification in diseases and cancer is noteworthy. The disorder of tRNA fragmentation induced by DNMT2 leads to high-fat-diet-induced metabolic disturbance in sperm cells 103. The accumulation of tRNA-derived small RNA fragments due to NSUN2 mutation and the absence of tRNA m5C leads to reduced protein translation rates, which activates stress pathways and promotes neuronal apoptosis 105. NSUN2 also targets tRNAs in Purkinje cells and neuroepithelial stem cells, which regulate cell replication, differentiation, migration and neurocognitive development 19, 106. NSUN5 was reported to be a promoter of radial glial cell migration and cerebral cortex development 107. Based on these findings, the RNA m5C modification is strongly correlated with dysplasia and dysfunction of the nervous system. Diseases related to energy metabolism disorder are also associated with the mitochondrial RNA m5C modification. For example, NSUN3 may be associated with multisystem mitochondrial disease associated with a combined oxidative phosphorylation deficiency 108. In leukemia cells, NSUN3/DNMT2 and NSUN1 regulate the formation of 5-azacitidine-sensitive chromatin structures in an antagonistic manners 25. Additionally, the canonical DNA demethylase TET2 was reported to mediate mRNA m5C that leads to myelopoiesis in infections, such as sepsis and parasitosis, in the mammalian system 91. The RNA m5C modification in malignant solid tumors has been a focus of cancer research at the epigenetic level. Various m5C writers and readers play crucial roles in cancer progression, including cell proliferation, differentiation, migration, invasion and drug sensitivity. Taking the typical m5C methylase NSUN2 as an example, NSUN2 has been shown to participate in multiple pan-cancer pathways: promoting cell progression, migration and invasion in breast cancer 57, 109; promoting tumorigenesis and development in skin cancer 27; promoting cell growth, tumor progression and metastasis in urothelial carcinoma of the bladder 54; promoting tumorigenesis and cell proliferation in gall bladder cancer 110; increasing the sensitivity of HeLa cells to 5-fluorouracil 28; promoting cell migration, invasion and drug resistance in esophageal squamous cell carcinoma (ESCC) 111; promoting proliferation in gastric cancer 112; promoting tumorigenesis, migration and invasion in hepatocellular carcinoma (HCC) 113. NSUN4, NSUN5, NSUN6 and NSUN7 are associated with cancer development in HCC, head and neck squamous cell carcinoma (HNSCC), pancreatic cancer and glioma 29, 114-116. In addition, the tumor immune microenvironment is affected by NSUN2 and NSUN6 through multiple pathways, such as the regulation of RNA metabolism, the cell cycle and immune cell activation 117. In addition to the NSUN family-induced RNA m5C modification in cancer, DNMT1 overexpression directly leads to hypermethylation of tumor suppressor genes, which results in lung tumorigenesis and a poor prognosis 26. Regarding m5C readers, ALYREF is associated with tumor progression in patients with glioblastoma and HCC, but regulates glucose metabolism and tumorigenesis in individuals with bladder cancer 29, 118. YBX1 promotes cell growth, tumor progression and metastasis in bladder urothelial carcinoma 54. More importantly, m5C readers are associated with cancer development in collaboration with methylases 54, 119. For the TET family, a downregulated RNA hm5C level was reported in cancerous tissues compared to adjacent normal tissues in human colorectal carcinoma and hepatocellular carcinoma, suggesting possible anticancer mechanisms 120. In general, upregulated RNA m5C components and high levels of the m5C modification are significantly correlated with malignancy and a poor prognosis in patients with the cancers mentioned above and some other cancer types, such as head and neck squamous cell carcinoma (HSNCC) and ovarian cancer 27, 121, 122. In addition to eukaryotes, in RNA virus HIV-1, the transcription and replication of TAR RNA are restricted by NSUN1 induced RNA methylation 20, while the splicing and translation of mRNA are related to NSUN2-induced RNA methylation 123. The efficient prolongation of HIV latency in CD4+ T cells suggests a possible treatment for acquired immune deficiency syndrome.

Functional role of RNA m5C in facilitating metastasis

As the first beneficiary in the field of nucleic acid methylation, m6A in RNA possesses multiple epigenetic regulatory activities in various biological processes, diseases and especially cancer 124. With a specific regulator, RNA m5C can mediates the activation of oncogenic pathways and forms a microenvironment suitable for the migration and metastasis of various cancer cell lines (Table 1). For instance, NSUN5 and NSUN6 were reported to be associated with metastasis in skin cancer and breast cancer. The former methylase and the specific reader ALYREF are overexpressed in metastatic stage of head and neck squamous cell carcinoma 119. Although the latter participates in RNA-protein interactions, an MST1/2-antagonizing lncRNA for YAP activation inhibits the activity of macrophage stimulating 1 (a protein serine kinase) in an NSUN6-dependent manner, which facilitates bone metastasis in breast cancer 125. In urothelial carcinoma of the bladder, NSUN2 targets the 3' untranslated region (3'-UTR) and stabilizes the mRNA of HGDF by generating the RNA m5C modification, while the reader YBX1 binds to the m5C region with the help of the partner protein ELAVL1 (an mRNA stability maintainer). The activation of the NSUN2/YBX1/HDGF axis was proven to promote cell growth, tumor progression and metastasis 54. The expression levels of NSUN2 and NSUN3 are downregulated by knocking out proto-oncogenic isozymes (sphingosine kinases 1 and 2, SK1 and SK2) in metastatic prostate cancer and breast cancer. SK1 and SK2 silencing alter the activation of protumorigenic genes relevant to classic membrane signal transduction pathways, such as epidermal growth factor, the EMT, cell cycle, cell motility and DNA stability 126. NSUN2 recognizes and binds to the canonical lncRNA H19 and NMR (NSUN2 methylated lncRNA). In ESCC, methylated NMR interacts with bromodomain PHD finger transcription factor (BPTF) and leads to the overexpression of oncogenes (MMP3 and MMP10) that are involved in cancer cell migration and invasion by activating ERK 1/2 111. Although H19 expression is elevated in various tumors, the lncRNA is stabilized by the NSUN2-induced m5C modification, which specifically binds to oncoprotein G3BP1. The mechanism was verified to be associated with tumorigenesis, malignancy and cell migration and invasion. Poor differentiation of cancer cells was observed in H19-overexpressing hepatocellular carcinoma 113. The mRNA encoding autotaxin (ATX) is one target of NSUN2. ATX and its product are famous for exerting multiple membrane functions and mediating cancer development, and activation of the NSUN2/ATX/ALYREF axis promotes mRNA nucleus to cytoplasm transport and cell migration in glioma 127. NSUN2 induced tRNA methylation in neuroepithelial stem cells also mediates differentiation and migration. The underlying mechanism is related to the activation of chemoattractant fibroblast growth factor 2 (FGF2), which facilitates cell maturation and cellular activities 106. Moreover, following the upregulation of NSUN2, the proliferation and migration of HEK 293 cells is enhanced by the overexpression of oncogenes that are associated with the cell cycle, focal adhesion, TGF-β signaling pathway and Notch signaling pathway 52, 128. Taken together, NSUN2 is a notable biomarker for predicting tumor metastasis and the prognosis and a promising therapeutic target in clinic applications. Although NSUN2 overexpression was reported to promote metastasis and cell invasion by promoter methylation 109, these studies explicitly indicate that NSUN family-induced RNA m5C modifications play a pivotal role in tumor metastasis and cell motility (Figure 2).
Table 1

M5C RNA methylation induced cell migration and metastasis

Cell typeM5C componentRoleEffectsRefs
Bladder urothelial carcinomaNSUN2 & YBX1Writer & readerNSUN2 stabilize the mRNA of HDGF, while YBX1 bind to m5C methylation with a partner protein ELAVL1 and promote cell growth, tumor progression and metastasis 54
Breast cancerNSUN2WriterNSUN2 overexpression promotes metastasis and invasion of breast cancer 109
Breast cancerNSUN6WriterThe antagonizing lncRNA for YAP activation inhibits activity of the protein serine kinase MST1 in a NSUN6-dependent way, which facilitates bone metastasis in breast cancer 125
ESCCNSUN2WriterNSUN2 methylated lncRNA bind to chromatin regulator BPTF and promotes MMPs expression through ERK pathway 111
GliomaNSUN2WriterNSUN2 deficiency inhibits glioma cell migration by striking autotaxin and lysophosphatidic acid associated pathway 100
HCCNSUN2WriterNSUN2 methylated H19 bind to oncoprotein G3BP1, which may be associated with tumor genesis, migration and invasion 113
HEK 293 cellNSUN2WriterNSUN2 promote cell proliferation and migration by regulating oncogenes that are associated with cell cycle, focal adhesion, TGF-β signaling pathway and Notch signaling pathway52, 128
HNSCCNSUN5 & ALYREFWriter & readerALYREF and NSUN5 are overexpressed in metastasis stage of head and neck squamous cell carcinoma 119
Neuroepithelial stem cellsNSUN2WriterNSUN2 mediate FGF2 induced migration and differentiation of neuroepithelial stem cells 106
Prostate and breast cancerNSUN2WriterExpression level of NSUN2 and NSUN3 are regulated by proto-oncogenic isozymes (sphingosine kinases 1 and 2) in prostate metastasis cancer and breast cancer, by a possible mediation of epidermal growth factor associated cell migration 126
Prostate cancerDNMTsWriterDNMT1, DNMT2, and DNMT3 are involeved in lymph node metastases of prostate cancer 144

M5C writers and readers function as promoters of metastasis in pan-cancer. ESCC, esophageal squamous cell carcinoma. HCC, hepatocellular carcinoma. HNSCC, head and neck squamous cell carcinoma

Figure 2

Molecular interactions between m5C components and metastasis related genes. M5C writers promote metastasis in various cancers by regulate oncogenes or suppressor genes. Several writers and readers are associated with cancer metastasis by unclear mechanism. Methylase and binding protein for m5C can work synergistically and promote metastasis.

As an immature RNA methylase family, the relationship between the DNMT-induced m5C modification and cell mobility or metastasis remains unclear. However these proteins play a supporting role in pathways through which tumor suppressor genes function in a DNA methylation-dependent pattern. For example, DNMT1 activity is increased by high level of specificity protein 1 (SP1)-induced endogenous p53 inactivation in lung cancer, while p53 is now better known for its anticancer effect than as an oncoprotein in various tumors, as it is associated with cell survival, invasion, tumor growth, metastasis, the EMT and multiple pro-oncogenic signaling pathways 129. Analogously, TETs-associated DNA demethylation mediates metastasis in malignancies such as hepatocellular carcinoma and lung cancer 130, 131. The abovementioned effects of these writers, demethylases and readers on DNA 5mC do not refute their potential to mediate metastasis and cell migration. More research on m5C modification at the transcriptional level and related oncogenic pathways is needed to improve our knowledge of the epigenetic regulation of tumor metastasis.

Conclusions

Epigenetic modification is increasing in significance in biological processes. The elucidation of nucleic acid methylation has been reported in recent years. Our review focused on the RNA m5C modification in tumor cells and other diseases is inevitably deficient and has the potential for further exploration. The m5C modification may not be as popular as sibling methylation m6A, but it is still an integral part of epigenetic modification. Abundant writers and readers for RNA m5C have been identified, leading to a variety of interactions and regulation of biological processes. Typically, DNMT2 recognizes and methylates tRNA through a highly conserved region that was previously linked to DNA methylation. Along with NSUN2, NSUN3 and NSUN6, these enzymes target tRNAs and participate in tRNA fragmentation and energy metabolism. NSUN1, NSUN4 and NSUN5 preferentially bind rRNA and induce the process of ribosome metabolism. For mRNA, DNMT2 and NSUN2 are the main writers, since mRNA m5C is critical for numerous cellular biological processes, such as cell growth, differentiation, movement and RNA modification. Furthermore, NSUN2 and NSUN7 bind to noncoding RNAs that regulate cell metabolism 21, 55, 115. Writers of RNA m5C usually work in partnership with readers. YBX1 and ALYREF tend to recognize NSUN-induced methylation, which promotes the transportation and improves the stability of target mRNAs. YTHDF2, on the other hand, binds to m5C-modified rRNA at the same conserved residue for the m6A modification. Unfortunately, erasers for RNA m5C have not been comprehensively identified. Members of the well-known DNA demethylase family TETs trigger cascade oxidations, which may activate the underlying mechanism of RNA demethylation in the m5C region. Since a duality of methylation in DNA and RNA was found in m6A, m5C, hm5C and m1A modifications, studies aiming to identify whether a co-function of same methylation component induces RNA and DNA methylation or demethylation exists and the related mechanisms and outcomes are needed. Nevertheless, different types of RNA methylation are able to collaborate to regulate downstream targets and modulate the development of diseases. For example, NSUN2-mediated m5C collaborates with METTL-mediated m6A promote p21 expression, and various types of RNA methylation participate in glioma genesis and progression 132, 133. RNA m5C is relevant to numerous diseases, including energy metabolism disorders, hematopoietic system diseases, viral infection and the most remarkable pathological process, the development of malignancies. The expression of RNA m5C writers and readers is significantly correlated with a poor prognosis and the TNM classification of neoplasms. These writers and readers are mainly involved in pathways of tumorigenesis and metastasis in the brain, lung, breast, prostate and others tissue. Many cytokines, such as HDGF, TGF-β, FGF2 and G3BP1, which are validated tumor promoters, participate in cell migration and metastasis induced by the m5C modification, indicating a strong correlation between the RNA m5C level and mobility of cancer cells. Moreover, some studies discovered high RNA m5C levels in circulating tumor cells 134. Since the global amount of m5C in blood DNA was identified as a promising marker for cancer prognosis, increased general RNA m5C levels may be a novel indicator of metastasis. Nevertheless, a more comprehensive regulatory network for cancer cell transfer requires many mechanistic investigations of epigenetic modifications. RNA m5C has the potential to be a unique target for clinical cancer assessment and treatment. Regarding the existing targets of RNA m5C modification, gene therapy is a feasible treatment for RNA m5C-induced diseases and cancer development. By modifying the gene sequence of key RNA m5C methylases, such as NSUN2, reduced RNA methylation may prevent the occurrence of disease or reverse cancer progression. However, considering the non-specificity of gene therapy, a well-designed inhibitor based on molecular research may effectively reduce the function of a specific RNA m5C writer and reverse the development of diseases since inhibitors of m6A components are being used in cancer therapy. In addition, the upstream molecules that regulate the functional activity of the RNA m5C component may represent an optional treatment for diseases related to specific molecules. For example, aurora kinase B phosphorylates NSUN2 at Ser-139 and reduces RNA methylation levels, suggesting that regulation at the protein level is feasible 135. More research focused on molecular structures and functional pathways is needed to completely understand the effect of the RNA m5C modification and exploit it in clinical applications. However, barriers still exist to further RNA m5C research when the final goal is to fully understand the RNA m5C modification and translate the findings into the clinic. Regarding the detection and research trends of RNA m6A modification, detection methods based on homogeneous techniques are still evolving to obtain better resolution or sensitivity 136. We anticipate that RNA methylation detection is both a limitation in research and a key to breakthrough. Because traditional high-throughput techniques for identifying m5C sites are inefficient, computer-based learning techniques that quickly and accurately predict RNA m5C modifications are urgently needed. For example, the novel m5C detection method, direct RNA sequencing revealed a more complex transcriptome characterization than expected in Arabidopsis 137. New methods such as “iRNA-m5C” and “iRNA-m5C_SVM” for RNA m5C site detection with good predictive performance will be helpful in structural and functional research on the RNA m5C modification 138, 139. However, the immediate application of these new approaches will be a further obstacle in research and clinical translation. Integration of broad data sets and establishment of databases are also effective for improving RNA m5C research. Database websites such as “RMBase” integrate a large number of RNA methylation data for review and verification while “RMDisease” and “RMVar” have been applied in RNA modification-related disease research 140-142. Prediction tools such as “PEA-m5C” trained with the forest algorithm predict candidate m5C modification sites for functional research 143.

Authors' contributions

BXZ and ZGZ conceived this study and provided financial and administrative support. QFZ and FRL did most of the data generalization and summarization. WC, HRM and HFL help collecting supplement information. All authors further discussed about data and prepared the panels for tables and figures. QFZ wrote the manuscript. All authors read and approved the final manuscript.

Availability of data and materials

The researches that support the conclusion of this review have been referenced within this article.
  142 in total

1.  Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.

Authors:  Cécile Saint-Martin; Gwendoline Leroy; François Delhommeau; Gérard Panelatti; Sabrina Dupont; Chloé James; Isabelle Plo; Dominique Bordessoule; Christine Chomienne; André Delannoy; Alain Devidas; Martine Gardembas-Pain; Françoise Isnard; Yves Plumelle; Olivier Bernard; William Vainchenker; Albert Najman; Christine Bellanné-Chantelot
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

2.  NSUN2-Mediated m5C Methylation and METTL3/METTL14-Mediated m6A Methylation Cooperatively Enhance p21 Translation.

Authors:  Qiu Li; Xiu Li; Hao Tang; Bin Jiang; Yali Dou; Myriam Gorospe; Wengong Wang
Journal:  J Cell Biochem       Date:  2017-05-03       Impact factor: 4.429

3.  5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs.

Authors:  Xin Chen; Ang Li; Bao-Fa Sun; Ying Yang; Ya-Nan Han; Xun Yuan; Ri-Xin Chen; Wen-Su Wei; Yanchao Liu; Chun-Chun Gao; Yu-Sheng Chen; Mengmeng Zhang; Xiao-Dan Ma; Zhuo-Wei Liu; Jun-Hang Luo; Cong Lyu; Hai-Lin Wang; Jinbiao Ma; Yong-Liang Zhao; Fang-Jian Zhou; Ying Huang; Dan Xie; Yun-Gui Yang
Journal:  Nat Cell Biol       Date:  2019-07-29       Impact factor: 28.824

4.  The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors.

Authors:  Michaela Frye; Fiona M Watt
Journal:  Curr Biol       Date:  2006-05-23       Impact factor: 10.834

5.  Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA.

Authors:  Jeffrey E Squires; Hardip R Patel; Marco Nousch; Tennille Sibbritt; David T Humphreys; Brian J Parker; Catherine M Suter; Thomas Preiss
Journal:  Nucleic Acids Res       Date:  2012-02-16       Impact factor: 16.971

6.  RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data.

Authors:  Jia-Jia Xuan; Wen-Ju Sun; Peng-Hui Lin; Ke-Ren Zhou; Shun Liu; Ling-Ling Zheng; Liang-Hu Qu; Jian-Hua Yang
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

7.  Simultaneous targeting therapy for lung metastasis and breast tumor by blocking the NF-κB signaling pathway using Celastrol-loaded micelles.

Authors:  Yue Zhao; Yanan Tan; Tingting Meng; Xuan Liu; Yun Zhu; Yun Hong; Xiqin Yang; Hong Yuan; Xuan Huang; Fuqiang Hu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

8.  Archaeal NSUN6 catalyzes m5C72 modification on a wide-range of specific tRNAs.

Authors:  Jing Li; Hao Li; Tao Long; Han Dong; En-Duo Wang; Ru-Juan Liu
Journal:  Nucleic Acids Res       Date:  2019-02-28       Impact factor: 16.971

9.  NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs.

Authors:  Lindsey Van Haute; Song-Yi Lee; Beverly J McCann; Christopher A Powell; Dhiru Bansal; Lina Vasiliauskaitė; Caterina Garone; Sanghee Shin; Jong-Seo Kim; Michaela Frye; Joseph G Gleeson; Eric A Miska; Hyun-Woo Rhee; Michal Minczuk
Journal:  Nucleic Acids Res       Date:  2019-09-19       Impact factor: 16.971

10.  RNA cytosine methylation by Dnmt2 and NSun2 promotes tRNA stability and protein synthesis.

Authors:  Francesca Tuorto; Reinhard Liebers; Tanja Musch; Matthias Schaefer; Sarah Hofmann; Stefanie Kellner; Michaela Frye; Mark Helm; Georg Stoecklin; Frank Lyko
Journal:  Nat Struct Mol Biol       Date:  2012-08-12       Impact factor: 15.369

View more
  12 in total

1.  UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation.

Authors:  Jing-Zhu Cao; Gang Nie; Hao Hu; Xiao Zhang; Chen-Ming Ni; Zhi-Ping Huang; Guang-Lei Qiao; Liu Ouyang
Journal:  J Gastrointest Oncol       Date:  2022-06

Review 2.  The Methylation Game: Epigenetic and Epitranscriptomic Dynamics of 5-Methylcytosine.

Authors:  Adele Alagia; Monika Gullerova
Journal:  Front Cell Dev Biol       Date:  2022-06-03

3.  Prognostic Characteristics and Immune Effects of N6-Methyladenosine and 5-Methylcytosine-Related Regulatory Factors in Clear Cell Renal Cell Carcinoma.

Authors:  Lei Li; Zijia Tao; Yiqiao Zhao; Mingyang Li; Jianyi Zheng; Zeyu Li; Xiaonan Chen
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

4.  m5CRegpred: Epitranscriptome Target Prediction of 5-Methylcytosine (m5C) Regulators Based on Sequencing Features.

Authors:  Zhizhou He; Jing Xu; Haoran Shi; Shuxiang Wu
Journal:  Genes (Basel)       Date:  2022-04-12       Impact factor: 4.141

5.  The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.

Authors:  Chenxi He; Xinying Zhu; Fanting Kong; Xiaochong Zhang; Xiukun Chai; Chunyan Zou; Dongqiang Zhao
Journal:  Biomed Res Int       Date:  2022-06-07       Impact factor: 3.246

6.  Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications.

Authors:  Xinqian Geng; Zheng Li; Ying Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

7.  Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer.

Authors:  Rong He; Changfeng Man; Jiabin Huang; Lian He; Xiaoyan Wang; Yakun Lang; Yu Fan
Journal:  Front Genet       Date:  2022-04-06       Impact factor: 4.772

Review 8.  The Epitranscriptome in miRNAs: Crosstalk, Detection, and Function in Cancer.

Authors:  Daniel Del Valle-Morales; Patricia Le; Michela Saviana; Giulia Romano; Giovanni Nigita; Patrick Nana-Sinkam; Mario Acunzo
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

9.  Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma.

Authors:  Wei Wei; Chao Liu; Meng Wang; Wei Jiang; Caihong Wang; Shuqun Zhang
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

10.  An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer.

Authors:  Duo Yun; Zhirong Yang; Shuman Zhang; Hai Yang; Dongxue Liu; Robert Grützmann; Christian Pilarsky; Nathalie Britzen-Laurent
Journal:  Front Cell Dev Biol       Date:  2022-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.